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fj%je&a. Ws sought to determine wbii ion curreat predom- 
ioautly a&& defrbriliatioo outcomes by using specific phanna- 
eologic probes (liiocatw [a sodium channel blocking agent] and 
cesbnu [an outward potassium rtmnuel blocking age&]) in 26 
swine. 
Badtgmtad. Tbe e&t of a drug 011 sodium or potassium 
eltmmel condeetaum, or both, may atkt delibrillatioa threshold 
vahtes. However, it is uakuowu which ion charmel predominates. 
M~F,lICb&W8S~QdOln!~&%igDcdtOOlWOfbUr 
tiP&meut@popsuithhvotreatmeatpBases:greupI=placebo 
(D5W1Ce~~tpttaseIfol~by~~sresiumia 
-tpbaseH(lJ =Q);groiq2=lidocAefollawdby 
pluspptseema~n=‘I);gmq3=lidmkeb~by~ 
caiuepluscesium(n=‘I),group4=placebowtowedbyplarrbo 
phss p&web0 (0’ = 4). De6brillation tbmsbold values aud eketro- 
cardiograpdi uuasurements were obtained at baseliae sad RI 
tmntmentpbsstrsIandH. 
f&&s. livhcak iucwased fibrillation tbresbokl values 
from baseliue by 71% in group 2 (p = 0.02) hod by 92% in group 
3 (p < Wl). There were no ciumges in detlbrillutkm tlweshold 
values from baseline to DSW in groups 1 and 4. When DSW was 
added to lidocaine in group 2 and DSW in group 4. there were no 
stgniltcant changes in defibrillatiou tbreshoid values. However, 
when cesium was added to lidocaine in group 3, the elevated 
defibrillation tblwbold values (mean f SD) returued to baseline 
values (from IS.7 + 3.46 to 7.55 f 3.19 J, p c 0.01). Cesium added 
to DSW iu group 1 also significuntly reduced defibrillatioa tbwsb- 
old values from 7.10 f 127 to 4.14 + 1.75 J (p c 0.01). The elfect 
of c&urn on defibrillation tbresbold values was similar between 
groups 1 and 3, rega&ess of liiiue, such tbat these valaes 
were reduced by 40 f 14% aud 51+ 1896, respectively (p = 0.28). 
Car-. Cesium, through potassium blo&w& reverses 
liiue-iodeced elevatioo in defibrillatioa tbresbold valoes. ‘The 
ffiaguitude ofde6brilhtiou threshuld reduction when cesium was 
added to liiue was similar to the defibrillation tbresbuld 
reduaioo when &em was added to place&. Thus, inbibitiug 
ontmrd potassium conductauce aud pndoaging repolarizatiou 
decreases defibrillation threshold values iudepeudest of sodium 
channel blocMe. 
(J Am call caniial096;27:1534-42) 
Several antiarrhythmic agents have been shown to affect the 
defibriflation threshold of monophasii shocks (l-11). The 
exact mechanisms respons~iMe for these effects are not known, 
although it appears that a drug’s effect on sodium or potassium 
conductance, or both, may play a significant role (2). These 
studies have consistently shown (2,3,10,!1) that drugs which 
prolong cardiac repolarization but do not affect conduction 
velocity (outward potassium channel blocking agents [sotalol] 
or sodium channel activating agents [ibutelide]) lower the 
defibrillation threshold. In contrast, drugs that block cardiac 
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sodium channels and do not affect potassium conductance (i.e., 
lidocaine, O-desethyl encainide, moricizine) increase the en- 
ergy required for successful defibrillation (1,2 4 $9). DN~S 
that block sodium channels and also inhibit out ootassium 
channels have varied effects on the defibrillauon threshold 
(i.e., quinidine, procainamide) (2,5,6,8,9). These data have led 
to a paradigm that indicates that drugs which block sodium 
channels and decrease conduction velocity without affecting 
the action potential duration raised defibrillation threshold 
values, whereas drugs that block outward potassium channels 
and prolong the action potential duration (in the absence of 
changes in conduction velocity) d&ease defibrillation thresh- 
old values. 
Recent evidence suggests that the effec6 of potassium 
channel blockade (evident by action potential duration prolon- 
gaGon) on the defibrillation threshoh may predominate over 
the effects of sodium channel blockade (evident by a reduction 
in conduction velocity). Flecainide and propafenone increased 
defdxillation threshold values in a canine model (5.9) in which 
these drags slowed conduction velocity (>WZ increase in 
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QRS interval) W did not change the action pctential duration 
(<.5% increase in the corrected QT interval). However, these 
drugs either decreased or did not affect detihrillation threshold 
values in a swine model (7,s) in which they slowed conduction 
velocity and increased the action potential duration (>4W 
increase in the corrected JT interval). These species-specific 
disparate e5ects on repolarization appear to be responsible for 
the divergent drug e5ects on defibrillation threshold. It is 
possible that a lower drug atlinity for blocking canine omward 
potassium channels is responsible for these differences in 
repolarization (12). Therefore, these data imply that changes 
in potassium conductance influence defibrillation efficacy to a 
greater extent than changes in sodium conductance. 
However, the blockade of the fast sodium channel remains 
a mechanism by which antiarrhythmic drugs increase defibril- 
lation threshold becallse all antiarrhythmic drugs that have 
been shown (t-1 I) to increase de+ibrillation threshold values 
have sodium channel blocking activities. Nevertheless, it is 
possible that changes in outward potassium conductance can 
modulate the effect that a sodium channel blocking agent will 
iave on the defibrillation threshold. Because sodium channel 
blockers that also block outward potassium channels have a 
variable effect on defibrillation threshold, it remains unknown 
whether the effects of reduced sodium channel activity on 
defibrillation threshold can be overcome by blockade of out- 
ward potassium channels. 
The specific aims of the current “tudy were 1) to determine 
whether blocking outward potassium conductance can reverse 
elevated defibrillation threshold values produced by sodium 
channel blockade, and 2) to determine whether the e5ect of 
potassium channel blockade on defibrillation threshold is 
independent of sodium channel blockade. In the present study 
we used pharmacologic probes with specific effects on sodium 
and potassium conductance to determine the interrelation 
betwee? changes in ion conductance and defibrillation thresh- 
old. Lidocaine was used as a probe because it is a pure sodium 
channel blocker that does not a5ect potassium conductance 
and consistently elevates the defibrillation threshold (213). 
Cesium chloride was used because it is a global inhibitor of 
outward potassium channels (delayed and inward r&ifying 
potassium channels), does not affect sodium conductance and 
has been shown to decrease defibrillation threshold values 
(2,14). 
Methods 
.4nimat preparation ad surgical isstntntentatiou. Do 
mestic farm pigs weighing between 25 and 30 kg were used in 
this investigation. All procedures were approved by the Uni- 
versity of Cincinnati Institution Animal Care and Use Com- 
mittee before conducting the investigation. Qn he day before 
the procedure, the pigs were fasted ovcmight. On the morning 
of the investigation. the animals were premeditated with 
ketamine (IS mg!kg body weight) administered intramuscu- 
larly. Subsequently. pentobarbital(25 mg,kg) was administered 
intravenonsty for initial anesthesia induction. After intubation 
with an endotracheal cuffed tube, the animals were mechani- 
cally ventilated using a large-animal Harvard pump ventilator. 
A level plane of anesthesia was subsequently maintained 
throughout the study period using pentoharbital (demonstrat- 
ed not to affect defibrillation threshold [IS]), 7.5 to 150 mg 
intravenously every 30 to 60 min as needed. The femoral and 
external jugular veins and the femoral artery were cannulated 
for catheterization, drug infusion and blood collection. A 
combination pacing and contact monophasic action potential 
catheter (EP Technologies) was placed through the external 
jugular vein into the right ventricular apex under fluoroscopic 
guidance, to record monophasic action potential duration and 
for right ventricular pacing A pigtail 5F Mitlar pressure- 
sensing catheter was placed through the femoral arteq for 
blood pressure monitoring. Surface electrocardiographic 
(ECG) leads were placed on the four hmbs for monitoring 
leads 11 and aVF. The chest was opened using a mediastinot- 
omy. One M-cm2 ar d one 28-c-m titanium mesh patch elec- 
trode (mooels A and L 67, respe lively. Cardiac Pacemakers 
Inc.) were sutured onto the surface of the pericardium. The 
large electrode was placed over the anterior and lateral wall of 
the right ventricle, ahich was perpendicular to the small 
electrode placed over the lateraL$osterior~apical wall of the 
left ventricle. The elearodes were interfaced with an external 
defibrillator, where the right ventricular patch served as the 
anode. The defibrilhtor was capable of delivering a monopha- 
sic truncated waveform at a 65% fixed tilt with a p&c duration 
between 5 and 8 ms. Ike output of this device is determined by 
preset voltage adjustments (I-V increments) (Vent& ECU, 
Cardiac Pacemakers Inc.). The chest was dosed atier these 
procedures and chest tubes were placed into the pleural w 
and 4rained by suction. Arterial blood gases were measured 
every 20 to 30 mm to maintain an arterial pH between 737 and 
7.45, partial pressure of arterial oxygen between 83 and 
120 mm Hg and partial pr,ysure of carbon dioxide between 35 
and 45 mm Hg. Sodium and potasrium concentrations were 
measured every 30 min to maintain a serum sodium concen- 
tration between 135 and 144 mEq!liter and a serum potassium 
concentration between 3.4 and 4.4 mE@fiter (Nova 1. Raxter). 
Potassium concentrations remained B3.4 mE@iter after the 
initial instrumentation phase of the study. Rody temperature 
was monitored through a rectal probe and maintained at 37 to 
38°C using a surgical thermal blanket. Adequate hydration was 
maintained using lactated Ringer solution. 2 to 5 m5kg per h. 
study design. The experiment cons&d of three phases 
during which detibri5aticm threshotd and electroph$dogic 
vruiabk3 were measured: basehne and treatntent phases I and 
11 (Fig. 1). Each pig was randomly ass&ned to one of four 
groupsIgmcpI =baseiinefo5owedbyf’acebo(MW)fol- 
locuedbypbcebopluscesium(n=6):group2=baseline 
foiiowed by lidocahte followed by liine phrs ptacebu (n = 
7): l~oup 3 = baseline fdkmed by Mocaine fohowd by 
l&came plus cesium (tt = 7); grosrp 4 = baseline followed by 
placebofo5owedbypla&oplltsptacebo(n=6).’fhe~ine 
phase was started 30 mm after completion of insdnmtentatkm. 
Timtmm pkz.se I began immediiteiy after compl&n of the 
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F&am 1. Study design. 
baseline phase, where the treatment (D5W or lidccaine) was 
administered as a lO-min loading dose (20 m@g of lidocaine) 
foliowed by a continuous infusion (20 mgntg per h of lidocaine) 
(1). D5W, which served as placebo, was given in equal volume 
to the Iidocame infusion. Treormenr phase II began after the 
completion of treatment phase I, where lidocaine or D5W 
continued to be infused, and either cesium (OSmmoVkg load, 
l-m&/kg per h infusion) or DSW were added as a IO-min 
loading dose followed by a continuous infusion. D5W was 
given at the same infusion rate as if cesium were being infused. 
De6brillation threshold and other measurements were initi- 
ated 10 min after tbe end of the loading dose (20 min after 
initiation of loading dose) for both treatment phases, so that 
testing began after the drug distribution phase. Blood samples 
were obtained every 20 min during the drug phase for analysis 
of lidocaine concentrations. An immunoassay method (Abbott 
TDX, Abbott Laboratories) was used to measure lidocaine 
concentrations. 
IlelMMb tImeaId rle&&dh. Ventricular tibril- 
IatJon was induced by delivering, to the right ventricle, a 
stimulus drive train with a lC@ms cycle length for 2 s at a 
stimulw amphide of 10 V (model S8SO0, Grass Instruments). 
De-ion xhocks were applii using the truncated expo- 
nential waveform of preset energy levels. The time between 
defibriIIation trials was at least 4 mio, but not until arterial 
bIood pressure returned to within 10% of the preshock value. 
To qua&ate defibrillation threshold, a previously dexcrii 
step-down, xtep-up method was used (16). Energy, impedance, 
pulse width and peak current delivered to the myocardium 
were meaxured by the defibrillator and subsequently p&ted. 
‘I&e values are accurate to within 10% of oscilIoscopic 
measurements. The &Ebrillation threshold response for each 
teat was modeled according to the response at each energy 
level within a treatment phase using an iterative computer 
Cardiac Pacemakers Inc.) (16). 
&&k?%Aglobal assessment of ven- 
tricular conduction velocity wax determined by QRS duration 
through surface EC0 leads II and aVF during right ventricular 
pacing at a 350-ins cycle length. Myocanlial repolarimtion was 
asesed IocaIIy by right ventricular monophasic action poten- 
tiaIdura~altdgIobauybytheJTintervaIthroughsurface 
ECGIeadxduringtightventricuIarpacingatapacingcycle 
length of 3.50 ms. Ventricular pacing was continued for 15 s 
before measuring these variables. It is known that action 
potential duration and refractoriness take -2 min to com- 
pletely stabilize after a change in ventricular rate. However, 
95% of change in these variables occurs within the first 15 
beats. Our protocol measured these variables after 35 to 40 
beats (15 s) and took the average of 5 consecutive beats, which 
tends to smooth the oscillations present after the onset of 
ventricular pacing. 
The right ventricular effective refractory period was deter- 
mined by pacing the right ventricle for 8 beats using a stimulus 
intensity twice the diastolic threshold at a cycle ler.gtb of 
350 ms followed by one premature extrastimulus. The drive 
train was repeated after a 2-s pause, and the extrastimulus 
coupling interval was decremented by 2 ms until ventricular 
capture failed on two consecutive attempts. 
Wavelength; is the spatial extent of the depolarized, and 
therefore refractory, myocardium occupied by an impulse. It is 
the distance the impulse travels during the refractory period. 
Thus, the wavelength of an impulse is the product of conduc- 
tion velocity and refractoriness (17). The slower the conduc- 
tion velocity, the less time the impulse is occupied within 
refractory myocardium and, thus, the shorter the wavelength. A 
reduction in wavelength can produce an excitable gap and alIow 
reentry. In the present study, we appmated the wavelength by 
global measmementr of conduction velocity and repohGmtion 
bytakingthereciprocaloftheQRSdurationandmultiplyingitby 
the JT interval. 
All electrophysiologic measurements were obtained at the 
start of the defibrillation threshold protocol (20 min after 
beginning drug infusion, i.e., postdistribution phase), 30 min 
after tbe start of the defibrillation threshold protocol and at 
the end of the defibrillation threshold protocol for both 
baseline and drug treatment phases. These values were then 
averaged for each study phase. Electrophysiologic measure- 
ments were made in bimded manner using a digitizing pad 
interfaced with a computer program (Sigma Scan, Jan&l 
Scientific). 
L&&I anaIysis. A multivariate repeated measures analysis 
of variance with contrast was used to test differences between 
groups. Within-group comparisons (measurements using the 
pig as its own control) were determined by using a mixed- 
model analysis of variance looking at the comparisons of mean 
values for group and treatment phases (time) with a Bonferoni 
correction. The percent change in defibrillation threshold 
values from baseline to treatment phase I and from treatment 
phase I to treatment phase II were correlated with changes in 
global measures of myocardial electrophysiologic QRF and JT 
intervals and imp&e wavelength using regression and corre- 
lation analysis. Data are presented as mean value 2 SD, and 
p < 0.05 was considered significant. 
ReSUltS 
Detlbriilatios tf~reabold. Baseline mean defibrillation 
threxhoId values between the four groups were not signitintly 
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TaMe 1. Defibrillation Threshold Values 
studv Phase 
WI P ED,, P 
Ehere. (I) ValUC Peak Voltage Value 
Groua 1 
L&line (n = 6) 6.75 t ?.I 305 f fri 
D5W 7.10 ? 1.27 29ur6.l 
D5w + cscl 4.14 ” 1.75 240 I 44 
Group 2 
Baseline (a = 7) 9.78 + 3.91 wt.57 
l&c&e 15.7 i: S.&I 464 + 62 ’ 
<Cl III 
-1 
<lMll 
Iidocaine + DSW .6 ? MI 5 ~7  
Group 3 
Baseline (n = 7) ] <Il.01 336k3-4 453 51 1 <tl.rJl Lidamine 
’ <OB1 
2 
3i? 58 ) <O.Ol Lidocaine + CsCl 7.55 T 3.19 2 
Group 4 
Baseline (n = 6) 9.02 -e 3.92 .%I I su 
D5W 9.%+4.88 NS 3n3=77 NS 
JBW + DSW 11.4 5 4.61 403 f 57 
Dala presented are mean value + SD. CsCl = &urn chlwcle: ED,, = 
median e&tive dose. 
different (Table 1). In group 1 and 4 pigs, the defibrillation 
threshold values at baseline were similar to those determined 
during placebo treatment (Table 1). In groups 2 and 3, 
liine signiticantly increased defibrillation threshold values 
(median effective dose) from baseline by 71% (from 9.78 -t 
3.91 to 15.7 2 5.81 J, p = 0.02) and 92% (from 8.26 2 1.80 to 
15.7 t 3.46 J, p < O.Ol), respectively. When cesium was added 
. . . . io uoocame in groq 3 an.:! added to placebo in group 1, 
defibrillation threshold values decreased signiticantly by 51% 
(from 15.7 2 3.46 to 755 2 3.19 J, p < 0.01) and 40% (from 
7.10 2 1.27 to 4.14 2 1.75 J, p < O.Ol), respectively. In groups 
2 and 4, detibrillation threshold values did not change sig- 
nificantly when placebo was added to either liiine (from 
15.7 k 5.81 to 15.6 + 6.60 J, p = NS) or placebo (from 9.96 + 
4sR to 11.4 -c 4.61 J). 
The defibrillation threshold values in groups 2 and 3 were 
sikilar during lidocaine but were significantly diierent when 
these- values were compared with those during D5W in groups 
1 and 4. Overall, lidocaine increased defibrillation threshold 
values in groups 2 and 3 (71 + 43% vs. 92 2 28%. respextive- 
ly), whereas D5W had no effect in groups 1 and 4 (7 -t 21% 
and 8 lr 14%, respectively) (p < 0.01) (Fig. 2). When tium 
was added to liine in group 3 and to placebo in group 1, 
defibrillation threshold values decreased significantly. Overall, 
&urn decreased defibrillation threshold values in groups 1 
and 3 by a similar magnitude (51 -C 18% and 40 2 t4%. 
respectively) regardless of the presence of lidoc&e (p = 0.28) 
(Fig. 2). In contrast, tbe addition of D5W to Mocaine in group 
2 and of DSW to D5W in group 4 had no effect on 
defibrillation threshold values. However. defibrillation 
threshold V&eS during treatment pbase II in groups 1 and 
3 were significantly diEerent than those in groups 2 and 4 
(p < 0.01) (Fig. 2). 
vaubhka (Tbbie 2). In group I and 4 
pigs receiving placebo in treatment phase I, no changes were 
Treaimml Group0 1nabnantGmupr 
Fiirr 2. Box plots reprrwiting the change in nxdian effcctke dw~ 
r’t&,J detihrillation thrcsho!d (DFT) flue, from baseline to treat- 
ment phase I (I&I) and from treattncnt phar I to treatment phase II 
trig@) for each gromup. In treatment phase il. ccsium ws added to 
plac&o (MW) in group 1, placch2 lo ltdcrame in group 2. cewm to 
lidscaine in group 3 and plxelx~ to plxxtw in grwp 4. Omere&es of 
boxes = Lath and 75th pcrceniils~: crlndcd bars = l&h and V14h 
percentiles: bo&l lines within boxe? = methan v&w: dots wthin 
boxes = mean values. 
seen in any of the electrophysiologic measurements. Lidxaine 
administrdtion in groups 2 and 3 resulted in a si@kant 
slowing of ventricular conduction velociq. evident b\- a pro- 
longation in the QRS interral during righht ventricular pacing. 
Lidocaine also decrezxd the rcpolarizattin intenal. eklent 
by a reduction in the JT interval during pacing and a decrease 
in actiox~ potential duration. The decrease in tk indexes of 
repolarization were of smaller magnitude than the slowing of 
conduction and reached signiticance for the paced JT internal 
and action potential duration at 9OG repolarization in group 3 
and tended toward significance in group 2. The right vemric- 
ular etkctive refractory period was not significantly affected by 
lidocaine, although there was a trend toward increased values 
over baseline. L&cake also sign&~@ reduced the wave- 
length in groups 2 and 3. The addition of placebo to lidccaine 
in group 2 and to placebo in group 4 had no effe&T on 
electmphysidogic variables except for a further reduction in 
the JT interval and a prolongation of the effective refract05 
period in group 2. Howticr. the addition of cesium to lick+ 
caine in group 3 prokmged repotarization cvidcnt @ signifi- 
cant increases in the JT inter+4 and action potential duration. 
thereby reversing the effect of iidocaine on repolakation. The 
additbn of cesium tc lidocaine also tirrther slaapd conduction 
velocity. pdonged the effectk refracZory period arid de- 
creased bean rate. Simii findii owurred ruben cesium was 
added to placeb in group 1. but the increase m action 
potential duratioa did not reach stat&ii signikancc. and 
there were no changes in amduction velocity. 
T%c percent change in defibrillation tkshoid valalue~ horn 
baseline to treatment phase I showed a sign&ant correlation 
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Table 2. Eiectrophysiolc~c Variables 
Sinus Rhythm 
Paced Rhythm 350 ms 
” (RR interval [ms]) ORS lnkwal (ms) JT Inmal (mc) At%, fms) ERP (mr) Wavelength 
Byline 6 511 293 90 f IO I94 2 IO 235 + 8 213 t 14 2.2 c fl.3 
MW 6 520+75 901 I4 IY4 z I4 231 rs 213 t I4 2.2 2 0.5 
MWtCSCl 6 583 zt Ml? 91 z I? 2ar21’t 2402 II 222 2 14.t 2.3 2 0.5 
Group2 
Baseline 7 451 ? IO5 89Zh lY4 2 20 220 k IS 212 2 ?I 22 c 0.4 
tidoaine 7 .ln-c93 109 f 10’ IW’IR 213 c 32 223 t I9 I.7 + 0.1’ 
~doginet mw 7 45l-r65 IUY 5 148 I79 + 19’ 310 i- 24 237 i 14’ I.6 -t O.l* 
Gmup3 
L!a?elinc 7 51**52 97 + 8 ,xm ? 23 235 i IO 218 + I3 ?.I ? 0.3 
tidacaii 7 415 2 39 I16 2 13’ 179‘19 220 2 14 223 t 14 1.6 ~0.2’ 
Liieaim + cscl 7 54-l + 42+ 130 2 17-t 19s t 17t 232 2 I& 210 r I7 1.5 i- 0.3’ 
-up4 
Baseline 6 44of44 91 2 2 I82 z 15 225 b 16 2txr9-l 2.2 f 0.3 
D5W 6 442Z45 9022 185 t 13 224 2 19 207r14 2.2 f 0.4 
DSW t WW 6 447Z65 94 2 5.0 189 _C I? 22Rt 14 21: r ?I 2.3 + 0.5 
l p c 0.05 versus ha&x. tp < 0.05 versw previous phase. Data presented are mean value + SD. APD u, = action potential duration at YflcC repolarbation: ERP = 
effective refmcmy period. 
with percent change in QRS interval, JT interval and wave- 
length (Fii. 3). However the percent change in defibrillation 
threshold values from treatment phase I to treatment phase II 
correlated only with the JT interval (Fig. 3). 
trations during cesium administration was similar to that 
reported by others (2). 
Lidocaioe mad ekctdyte coneeatrutlnns. The dose of li- 
docaine achieved steady setxm concentrations from the 20-min 
point onward, which was the point at which the defibrillation 
threshold study protocol started. These concentrations ranged 
from 10 to 12 &ml in 2 and 3 and were not statistically groups 
diiferent between groups when the area under the plasma 
concentration time curve or diierences between groups over 
time using analysis of variance with repeated measures were 
compa=d 
Discussion 
Mean Serum sodium concentrations did not diier among 
the groups during baseline and treatment phases I and Il. 
Serum sodium concentrations ranged from 138 to 144 mmol/ 
liter in 1, 137 to 142 mmol/liter in 2, 136 to 143 group group 
mmoliliter in grolip 3 and 136 to 145 mmol/liter in 4 over group 
the entire study period. Potassium concentrations remained 
constant in each treatment group during baseline and treat- 
ment phase I for group 1 (3.6 t 3.1 and 4.0 t 02 mmoyliter, 
respectively), group 2 (3.8 t 0.3 and 4.1 + 0.3 mmol/liter, re- 
spectively), group 3 (3.6 % 0.2 and 3.9 2 0.3 mmol/liter, 
tqestkeiy) and group 4 (3.8 + 0.22 and 4.15 ? 0.38 
mmol/liter, respectively). However, mean serum potassium 
concentrations during treatment phase II increased sipifi- 
cantly when cesium was admiiered in groups 1 and 3 (from 
4.0 -c 0.2 to 5.3 2 0.3 mmDi/liter and from 3.9 -t 0.3 to 5.0 t 
0.6 mmol/liter, respectively, p < O.oOl), whereas potassium 
concentrations did not change when placebo was admiiered 
to group 2 or 4 in thii treatment phase (from 4.1 It 0.3 to 4.12 
0.2 mmoi,%ter and 4.15 2 0.38 to 4.21 It b.35 mmolMer, 
req&vely,p=NS).Themildincreaxinpotassiumconcen- 
Numerous studies (l-l 1) have suggested that the blocking 
effect of a drug on sodium or potassium channels, or both, may 
effect defibrillation threshold values. However, these studies 
did not determine which ion channel predominantly affected 
defibrillation outcomes. There were three major findings of the 
present study: 1) Elevated defibrillation threshold values pro- 
duced by sodium channel blockade (lidocaine) can be reversed 
to baseline values by blocking outward potassium conductance 
and prolonging repolarization through the administration of 
c&urn chloride. 2) Potassium channel blockade (cesium) 
added to sodium channel blockade (lidocaine) produced an 
increase in repolarization time and a further reduction in 
conduction velocity. Despite this slowing in conduction veloc- 
ity, cesium reduced defibrillation threshold values to pre- 
@iocaine values. 3) The c&urn-induced decrease in delibril- 
lation threshold values was independent of sodium channel 
blockade (lidocaine), where the magnitude of defibrillation 
threshold reduction when cesium was added to lidocaine was 
similar to the magnitude of defibrillation threshold nxhiction 
when cesium was administered during placebo. These findings 
support the conclusion that the effects of potassium channel 
blockade on defibrillation e%cacy predominate over the ac- 
tions of sodium channel biodmde. 
Prevkms s&dies. One previous study (2) investigated the 
relative changes in defibriilation threshold with sodium and 
potassium chmmel blockade. That study attempted to reverse 
the effect of lidwake on defibrillation threshold values by 
using the potassium dmmel blocker N-acetylprocaioamide in 
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dogs. Similar to the current study, lidocaine significantly 
increased defibrillation threshold values by - 100%. However, 
when N-acetylprocainamide was added to lidocaine, the deti- 
brillation threshold values were not significantly ditTerent from 
Fit 3. Relation between percent change in median effect&e dose 
defibrillation threshold (Dff) and percent change in QRS duration+ 
corrected JT (JTc) iatelval and impulse navekngth from baseline to 
treatment phase 1 (lop mw) and from treatment phase 1 to treatmenl 
Dhase II tllaaem rv1). 
those. with lidocaine alone, although the defibrillation thresh- ’ 
old values did decline by a small magnitude. Recent evidence 
with propafenone and %cainide (X7-9) also suggested that toriness (postrepoltition refractoriness). These effects rig.: 
the effects of potassium channel blockade on defibrillation consistent with previously reported data (1.2;. cesium in- 
threshold may predominate over the effects of sodium channel creased the time to repolarization and the refractory period 
blockade. Although these previous studies suggest the interre- when given with placebo, which is consistent with its potassium 
lation between sodium and potassium conductance on defibril- channel blocking effects, During lidocaine, cesium bad a 
lation efficacy, they are inconclusive. The data from the current similar effect on repolarization but also potentiated the effect 
study may differ from the previous study using lidocaine and of lidocaii on ventricular conduction velocity, evident by a 
N-acetylprocainamide because of differences in species or the further increase in paced QRS duration by 134. These find- 
use of cesium, a more potent and less specific potassium ings are most likely due to the effect of cesium on prokqing 
channel blocker than N-aoetylprocainamide. The degree of action potential duration. With an increase in action potential 
hyperkalemia caused by cesium was mild, and it is therefore duration, the sodium channel remains in an inactivated state 
unlikely that it is responsible for’the diierences. Nevertheless, for a longer period of time. Because the effects of lidocaine 
the inferential evidence from previous studies is consistent are predominant when the sodium channel is in an open! 
with the tindings ot the present study that the effects of inactivated state, the slowing of conduUion velocity is greater 
potassium channel blockade predominate over those of sodium (18,19). It is also possible that mild hyperkalemia produced by 
channel blo&ade on defibrillation threshold values. cesium could further potentiate the sodium channel blocking 
-. :+ii aetimi. In the current study, lido- effects of lidocame by depolarizing the rest membrane poten- 
Caine significa& slowed ventricular conduction velocity and tial and further inactivating available sodium ChanneJS (B). 
deeread tk time to repokuization (reduction of the JT Re@dks~ofthesecbar&~inoorldudionveiodty,~~ 
intervA and action potential duration) while increasing refrac- induced decrease in detibrillation threshold vaiues was unaf- 
1540 UJHELYI Fr AL 
DRUG-INDUCED CHANGES IN DERBRILLAllON THRESHOLD 
fecmd. This finding substantiates the hypothesis that the effects 
of potassium channel blockade on defibrillation threshold 
vahres predominate over those of sodium channel blockade. 
Thus, the electrophysiologic mechanism by which lidocaine 
increased defibrillation threshold values in treatment phase 1 is 
likely to differ from the mechanism by which cesium decreased 
defibrillation threshold values during treatment phase II. 
Our data aIso showed that a reduction in the JT interval and 
impulse wavelength and an increase in QRS duration corre- 
lated signiticantly with increases in defibrillation threshold 
vahres during treatment phase I. Thus, changes in several 
eleetrophysiilogic variables can predict the effect of lidocaine 
on detibrillation threshold values. However, during treatment 
phase II, or@ the JT interval prediied the change in defibril- 
lation threshold in the same manner as in treatment phase 1. 
During treatment phase II, cesium in group 3 slowed conduc- 
tion velocity; thus, the relation between QRS duration and 
detibrillation threshold was reversed. This also resulted in no 
net change in wavelength, and thus no correlation between 
wavelength and changes in defibrillation threshold. Thus, the 
effect of cesium on defibrillation could be predicted only by 
changes in the JT interval. Because there is a disparity between 
predictors of defibrillation between these sodium and potas- 
sium channel blockers, it is likely that these agents affect 
delibrihation by different mechanisms. The specific mechanism 
of how these agents cause changes in defibrillation outcomes 
cannot be determined from the present data. 
Rmposed mechanisms. The mechanisms by which changes 
in sodium or potassimn conductance affect defibrillation out- 
comes am not understood. There are two theories of failed 
defibrillation: 1) The shock stimulus was not strong enough to 
annihilate >90% of the original fibrillation wavefronts (exci- 
tation of a critical mass); or 2) the shock stimulus annihilates 
the initial fibrillation wavefronts but induces a postshock 
eleetrophysiologic state that results in the generation of a new 
fibrillatiott activation front (21-23). M&electrode recordings 
have shown (24,25) that the effects of high intensity shocks on 
depolarization (maximal diastolic potential), action potential 
duration and induced action potentials are not affected by 
tetmdotoxin (a sodium channel blocker). tt is also unbkely that 
cesium a&cted the amount of myocardium excited by the 
shock because most agents that are pure potassium channel 
blockers have minimal electrophysiologic actions at fast heart 
rates, such as fibrillation (reverse-use dependence) (26.27). 
However, it was evident from the microelectrode recordings 
that tetrodotoxiu did a&t the generation of spontaneous 
post&o& action potentials (2.5). Thus, it may be that sodium 
and potassium chamrel blockers do not affect the abiity of the 
shocks to annihilate the original fibrillation front but produce 
postshock eleetrophysiologic state that can either induce or 
prevent the propagation of early postshock activations (reen- 
try), resulting in failed or succe&d defibrillation respectively. 
Reentrant postshock activations and failed defibrillation 
may be caused by 1) a short impulse wavelength and thus an 
~~,2)~~~d~~~~a~tof 
tut increased refractory period dispersion, or 3) unidirectii 
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conduction velocity slowing (anisotropic propagation) (21,28- 
33). It is possible that lidocaine could enhance reentry by 
means of all these mechanisms. Lidocaine can shorten the 
impulse wavelength, as we have shown, by decreasing conduc- 
tion velocity while having a minimal effect on refractoriness. 
This would have the potential to create an excitable gap within 
a postshock circuit. Others (17) have shown that a reduction in 
impulse wavelength can predict the induction of atrial fibrillation! 
flutter. The other two mechanisms could also be responsible 
because sodium channel blockers have been shown (34-37) to 
increase dispersion in refractoriness and produce a greater 
degree of anisotropic propagation. 
In contrast, cesium could prevent postshock reentry by 
increasing refractoriness. This action would increase impulse 
wavelength and thus extinguish an excitable gap. However, 
when cesium was given concomitantly with lidocaine, conduc- 
tion velocity decreased significantly while slightly increasing 
refractoriness. Thus, we showed that cesium-lidocaine therapy 
did not affect wavelength, even though defibrillation values 
decreased significantly. It is also unlikeIy that cesium by itself 
can affect anisotropic conduction because this agent has no 
intrinsic effect on conduction velocity. It is possible that cesium 
could prevent reentry by decreasing refractory period disper- 
sion because it has been shown (38) that potassium channel 
blockers can reduce dispersion of refractoriness during paced 
rhythm. 
Study limitations. We used a swine model with a healthy 
cardiovascular system and a monophasic epicardial defibrilla- 
tion system. It is unknown whether these findings can be 
directly extrapolated to other defibrillation systems or to 
diseased (infarcted or myopathic) hearts (16). Moreover, ex- 
trapolation of these findings in a swine model to humans must 
be done with caution. However, the results from animal studies 
of antiarrhythmic drugs and monophasic defibrillation have 
correlated with experience in humans. It has been shown 
(l-11,39-48) that antiarrhythmic agents that increase defibril- 
lation threshold values in whole-animal models increase the 
defibrillation threshold or cause ventricular fibrillation to be 
refractoty to defibrillation in humans with cardiovascular 
disease. A recent meta-analysis (46) has confirmed these 
observations, showing a very close correlation between animal 
models of defibrillation and clinical data observed in humans. 
Moreover, a retrospective analysis (47) indicates that antiar- 
rhythmic agents are a responsible factor in producing higb 
defibrillation threshold values in patients with implanted defi- 
brillators. 
ClhtII implications. The clinical itr-rortance of elevated 
defibrillation threshold values was established when the inci- 
dence of sudden cardiac death it. patients with high defibrilla- 
tion threshold values (>25 J) was reported (48) to be sixfold 
greater than in patients with lower defibrillation threshold 
values (C?S J). These issues have become a daily problem 
because antiarrhythmic drugs have been shown (47) to a&et 
defibrillation threshold vahres and are used concomitantly in 
50% to 70% of patients with implanted detibrillators. We 
performed the present study using lidocaine concentrations 
higher than those used clinically for treating ventricular tachy- 
cardia but similar to concentrations seen after bolus infusions 
during cardiac arrest and resuscitation (49). Data from the 
present study indicate that it is possible to reverse antiarrhyth- 
mic drug-induced elevation in defibrillation threshold values by 
antiarrhythmic drugs that prolong repolarization through po- 
tassium channel blockade. It is also possible that acute admin- 
istration of a class III antiarrhythmic drug can be used as an 
emergency measure in patients refractory to defibrillation. 
This is contraxy to the present advanced cardiac life support 
protocol, which indicates the use of lidocaine (which increases 
defibrillation threshold) before class III antiarrhythmic agents, 
such as bretylium (which decreases defibrillation threshold) 
(2,50,51). 
Summary. The results of the present study imply that 
elevation of defibrillation threshold by antiarrhythmic drugs is 
dependent on both sodium channel activity and outward 
potassium conductance. However, blocking outward potassium 
channels lowers defibrillation threshold values independent of 
decreased sodium channel activity. Moreover, the present 
report shows that elevations in defibrillation threshold values 
produced by an antiarrhythmic agent can be reversed by 
another, which may have therapeutic potential in patients 
refractory to defibrillation. 
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